Biotech | January 03, 2022
Novavax submits data to U.S. FDA for Covid-19 EUA
Emergency Use Authorisation application request to be submitted following one month required by FDA EUA guidance
Emergency Use Authorisation application request to be submitted following one month required by FDA EUA guidance
SK bioscience secures long-term license to supply the Novavax vaccine for the Korean market
SAGE recommends additional third dose of the vaccine administered to immunocompromised persons
The vaccine will be manufactured and marketed in the Philippines by SII under the brand name Covovax
All modules required for regulatory review of Novavax vaccine, including CMC data, are now complete for WHO
The vaccine can be stored at 2 to 8 degrees celsius and traditional cold chain capabilities will suffice
Filing marks first protein-based vaccine submitted to MHRA for authorization
It is a recombinant nanoparticle protein-based vaccine
Study to explore heterologous regimen of COVID-19 vaccines from different manufacturers in adolescents 12-16 years of age
First participants enrolled in Phase 1 clinical trial of combination NanoFlu/NVX-CoV2373 vaccine with Matrix-M adjuvant. The Phase 1/2 study will also evaluate immunogenicity and safety
Subscribe To Our Newsletter & Stay Updated
